Nicox is an international ophthalmic company developing innovative solutions to help maintain vision and improve ocular health. Nicox’s lead program, NCX 470, is in Phase 3 clinical development (first Phase 3 trial completed, second Phase 3 trial ongoing) for lowering intraocular pressure (IOP) in patients with open-angle glaucoma or ocular hypertension. The Company is looking for commercial partnerships both for the U.S. and Japan. Nicox’s pipeline includes NCX 1728 in preclinical evaluation in retinal conditions and NCX 4251, a clinical stage asset for dry eye disease, licensed exclusively to Ocumension Therapeutics for the Chinese market. NCX 4251 is available for partnership outside of China. Nicox generates revenue from VYZULTA® in glaucoma, licensed exclusively worldwide to Bausch + Lomb, and ZERVIATE® in allergic conjunctivitis, licensed in multiple geographies, including to Harrow, Inc. in the U.S., and Ocumension Therapeutics in the Chinese and in the majority of Southeast Asian markets.